Less than two weeks after placating the rumor mill by officially announcing that it was evaluating "strategic alternatives," MGI Pharma Inc. agreed to be acquired by Eisai Co. Ltd. for $41 per share, or about $3.9 billion in cash. (BioWorld Today)